花园生物股价涨5.06%，南方基金旗下1只基金位居十大流通股东，持有347.85万股浮盈赚取313.06万元

Group 1 - Garden Biologics' stock increased by 5.06%, reaching 18.68 CNY per share, with a trading volume of 356 million CNY and a turnover rate of 3.65%, resulting in a total market capitalization of 10.152 billion CNY [1] - The company, Zhejiang Garden Biologics Co., Ltd., was established on December 18, 2000, and went public on October 9, 2014. Its main business focuses on developing, producing, and selling products related to a complete vitamin D3 industry chain [1] - The revenue composition of the company includes vitamin products at 47.41%, pharmaceuticals at 30.22%, lanolin and its derivatives at 20.93%, sales of raw materials and others at 1.01%, rental income at 0.31%, other trade products at 0.10%, and medical devices at 0.01% [1] Group 2 - Southern Fund's Southern CSI 1000 ETF (512100) is among the top ten circulating shareholders of Garden Biologics, having reduced its holdings by 48,400 shares to 3.4785 million shares, representing 0.65% of the circulating shares [2] - The Southern CSI 1000 ETF (512100) was established on September 29, 2016, with a latest scale of 78.996 billion CNY. Year-to-date returns are 8.61%, ranking 1564 out of 5569 in its category, while the one-year return is 34.61%, ranking 1862 out of 4295 [2] Group 3 - The fund manager of Southern CSI 1000 ETF (512100) is Cui Lei, who has been in the position for 7 years and 98 days. The total asset scale under management is 137.02 billion CNY, with the best fund return during the tenure being 251.88% and the worst being -15.93% [3]